SI3104838T1 - Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev - Google Patents

Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev

Info

Publication number
SI3104838T1
SI3104838T1 SI201531085T SI201531085T SI3104838T1 SI 3104838 T1 SI3104838 T1 SI 3104838T1 SI 201531085 T SI201531085 T SI 201531085T SI 201531085 T SI201531085 T SI 201531085T SI 3104838 T1 SI3104838 T1 SI 3104838T1
Authority
SI
Slovenia
Prior art keywords
therapeutic
making
methods
same
nanoparticles
Prior art date
Application number
SI201531085T
Other languages
English (en)
Slovenian (sl)
Inventor
Maria Figueiredo
Erick Peeke
David Dewitt
Geen Hoven Christina Van
Greg Troiano
James Wright
Young-Ho Song
Hong Wang
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI3104838T1 publication Critical patent/SI3104838T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201531085T 2014-02-13 2015-02-13 Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev SI3104838T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939363P 2014-02-13 2014-02-13
EP15707019.4A EP3104838B1 (en) 2014-02-13 2015-02-13 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
PCT/US2015/015887 WO2015123562A1 (en) 2014-02-13 2015-02-13 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Publications (1)

Publication Number Publication Date
SI3104838T1 true SI3104838T1 (sl) 2020-04-30

Family

ID=52595474

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531085T SI3104838T1 (sl) 2014-02-13 2015-02-13 Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev

Country Status (11)

Country Link
US (2) US10080723B2 (cg-RX-API-DMAC7.html)
EP (1) EP3104838B1 (cg-RX-API-DMAC7.html)
JP (1) JP6573895B2 (cg-RX-API-DMAC7.html)
CA (1) CA2939261C (cg-RX-API-DMAC7.html)
DK (1) DK3104838T3 (cg-RX-API-DMAC7.html)
ES (1) ES2770733T3 (cg-RX-API-DMAC7.html)
HU (1) HUE047934T2 (cg-RX-API-DMAC7.html)
PL (1) PL3104838T3 (cg-RX-API-DMAC7.html)
PT (1) PT3104838T (cg-RX-API-DMAC7.html)
SI (1) SI3104838T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015123562A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939261C (en) 2014-02-13 2023-03-28 Bind Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
AU2015280417B2 (en) 2014-06-24 2020-01-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
RU2018105118A (ru) * 2015-08-21 2019-09-23 Пфайзер Инк. Терапевтические наночастицы, содержащие терапевтический агент, и способы их получения и применения
CA3018292A1 (en) * 2016-03-22 2017-09-28 Pfizer Inc. Process for preparing therapeutic nanoparticles
WO2018208993A1 (en) * 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
WO2019090030A1 (en) 2017-11-03 2019-05-09 Prudhomme Robert K Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
CN112236459A (zh) * 2018-04-23 2021-01-15 灰色视觉公司 改善的连续微粒制造
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
AU2023383352A1 (en) * 2022-11-18 2025-06-05 Haima Therapeutics, Llc Lyophilization buffers for peptide-decorated liposomes
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869884B2 (en) * 2002-08-22 2005-03-22 Chartered Semiconductor Manufacturing Ltd. Process to reduce substrate effects by forming channels under inductor devices and around analog blocks
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
EP2309990B2 (en) 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EA032943B1 (ru) 2012-09-17 2019-08-30 Пфайзер Инк. Способ получения терапевтических наночастиц (варианты) и терапевтическая наночастица (варианты)
CA2885022A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
PL3046584T3 (pl) * 2013-09-16 2017-11-30 Astrazeneca Ab Terapeutyczne polimeryczne nanocząstki i sposoby ich wytwarzania i stosowania
CA2939261C (en) 2014-02-13 2023-03-28 Bind Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HUE043964T2 (hu) * 2014-03-14 2019-09-30 Pfizer Terápiás szert tartalmazó terápiás nanorészecskék és eljárás ezek elõállítására és alkalmazására

Also Published As

Publication number Publication date
PT3104838T (pt) 2020-02-14
CA2939261C (en) 2023-03-28
JP6573895B2 (ja) 2019-09-11
JP2017505800A (ja) 2017-02-23
EP3104838A1 (en) 2016-12-21
DK3104838T3 (da) 2020-02-24
US10583092B2 (en) 2020-03-10
EP3104838B1 (en) 2020-01-01
WO2015123562A1 (en) 2015-08-20
US20170042828A1 (en) 2017-02-16
US10080723B2 (en) 2018-09-25
ES2770733T3 (es) 2020-07-02
CA2939261A1 (en) 2015-08-20
US20190111004A1 (en) 2019-04-18
PL3104838T3 (pl) 2020-07-13
HUE047934T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
IL257318A (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
ZA201606646B (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
IL250415B (en) Antibodies against pd-l and methods of using them
GB2554283B (en) Devices for simulating a function of a tissue and methods of use and manufacturing thereof
SG11201703298SA (en) Activated bifidobacteria and methods of use thereof
PT3104838T (pt) Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas
SG10201406612RA (en) Mask structures and methods of manufacturing
GB201502084D0 (en) Catheter devices and related methods
GB201418350D0 (en) Dispenser and methods of use thereof
GB201404470D0 (en) Therapeutic methods and materials
HUE050761T2 (hu) Vegyületek és alkalmazási eljárások
IL249894A0 (en) Targeted medical nanoparticles and methods for their preparation and use
IL253234A0 (en) Methods for transdifferentiation and methods to use them
IL259047A (en) Nanoparticles containing a therapeutic substance, a process for their preparation and uses
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201802134B (en) Therapeutic compounds and methods of use thereof
ZA201606450B (en) Compounds and their methods of use
PT3129398T (pt) Novos agentes médicos e usos dos mesmos
GB201418809D0 (en) Therapeutic agents and uses thereof
IL252508A0 (en) Oxidized lipids and their uses
GB201417248D0 (en) Compostion and methods of treatment
GB201408171D0 (en) Formulation and method of manufacture
GB2588276B (en) Devices for simulating a function of a tissue and methods of use and manufacturing thereof
GB201403697D0 (en) Compounds and methods of use
GB201613145D0 (en) Toy apparatus and methods of manufacture and use thereof